Related Experiment Video
Updated: Mar 31, 2026

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
Published on: August 2, 2024
Left Ventricular Unloading in High-Risk Percutaneous Coronary Intervention
Divaka Perera1,2, Matthew Ryan1,2, Saad M Ezad1,3
1School of Cardiovascular and Metabolic Medicine and Sciences, King's College London, London.
Insights
Elective left ventricular unloading using a microaxial flow pump did not improve outcomes for patients with severe left ventricular dysfunction undergoing complex percutaneous coronary intervention. This strategy did not reduce major adverse clinical events compared to standard care.
Area of Science:
- Cardiology
- Interventional Cardiology
- Heart Failure Management
Background:
- Complex percutaneous coronary intervention (PCI) in patients with severely impaired left ventricular function poses significant risks.
- The efficacy of percutaneous left ventricular unloading in improving outcomes for these high-risk patients remains uncertain.
Purpose of the Study:
- To evaluate whether elective percutaneous left ventricular unloading using a microaxial flow pump improves clinical outcomes in patients with severe left ventricular dysfunction undergoing complex PCI.
Main Methods:
- A randomized controlled trial involving 300 patients with severe left ventricular dysfunction and extensive coronary artery disease.
- Patients were assigned 1:1 to either elective unloading with a microaxial flow pump or standard care during complex PCI.
- The primary outcome was a hierarchical composite of death, stroke, myocardial infarction, cardiovascular hospitalization, or myocardial injury at 12 months, analyzed by win ratio.
Main Results:
- At a median follow-up of 22 months, 36.6% of comparisons favored the microaxial flow pump, and 43.0% favored standard care (win ratio, 0.85; P=0.30).
- All-cause mortality was higher in the microaxial flow pump group (47 patients) compared to the standard care group (33 patients).
- No significant differences were observed in bleeding or vascular complications between the groups.
Conclusions:
- Elective left ventricular unloading with a microaxial flow pump did not reduce the risk of major adverse clinical outcomes in patients with severely impaired left ventricular function undergoing complex PCI.
- The study suggests that this unloading strategy is not beneficial for this high-risk patient population within the observed timeframe.
Background:
Complex percutaneous coronary intervention (PCI) in patients with severely impaired left ventricular function carries a high risk of death and complications. Whether percutaneous left ventricular unloading improves outcomes remains unclear.
Methods:
We randomly assigned 300 patients with severe left ventricular dysfunction and extensive coronary artery disease in a 1:1 ratio to a strategy of elective unloading with a microaxial flow pump or to standard care during planned complex PCI. The primary outcome was a hierarchical composite that included death from any cause, disabling stroke, spontaneous myocardial infarction, hospitalization for cardiovascular causes, or periprocedural myocardial injury at a minimum of 12 months, as analyzed according to a win ratio.
Results:
A total of 148 patients were assigned to receive a microaxial flow pump and 152 to receive standard care. At a median of 22 months (interquartile range, 16 to 30), 36.6% of pairwise comparisons favored the microaxial flow pump, and 43.0% favored standard care (win ratio, 0.85; 95% confidence interval [CI], 0.63 to 1.15; difference, -6.4 percentage points; P = 0.30). Death from any cause occurred in 47 patients in the microaxial-flow-pump group and 33 in the standard-care group (hazard ratio, 1.54; 95% CI, 0.99 to 2.41). There was no material between-group difference in the risk of bleeding or vascular complications.
Conclusions:
Among patients with severely impaired left ventricular function undergoing complex PCI, elective left ventricular unloading with a microaxial flow pump did not reduce the risk of major adverse clinical outcomes at a minimum of 12 months. (Funded by the U.K. National Institute for Health and Care Research; CHIP-BCIS3 ClinicalTrials.gov number, NCT05003817.).
More Related Videos
06:10Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
03:40Point-of-Care Ultrasound for Peripheral Veno-Arterial Extracorporeal Membrane Oxygenation Without Left Ventricular Venting
Published on: January 17, 2025